CAM
VERV

ClariVest Asset Management’s Verve Therapeutics VERV Stock Holding History

ClariVest Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.85K Hold
584
– – ﹤0.01% 485
2024
Q2 		$2.85K Sell
584
-77,043
-99% -$484K ﹤0.01% 485
2024
Q1 		$1.03M Buy
77,627
+156
+0.2% +$2.07K 0.11% 263
2023
Q4 		$1.08M Buy
+77,471
New +$960K 0.06% 238

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

ClariVest Asset Management's VERV Position: Q3 2024 in Review

ClariVest Asset Management held its Verve Therapeutics (VERV) position steady in Q3 2024 at 584 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #485.

ClariVest Asset Management first reported a position in VERV in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.08M in Q4 2023. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • ClariVest Asset Management held 584 shares of Verve Therapeutics worth $2.85K as of Q3 2024.
  • ClariVest Asset Management left its Verve Therapeutics share count unchanged in Q3 2024.
  • Verve Therapeutics made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #485 holding.
  • ClariVest Asset Management first reported a position in Verve Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • ClariVest Asset Management's Verve Therapeutics position peaked at $1.08M in Q4 2023.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.